Moleculin Biotech (MBRX) Other Non-Current Liabilities (2016 - 2026)
Moleculin Biotech (MBRX) posted quarterly Other Non-Current Liabilities of $44000.0 for Q4 2025, down 99.89% quarter-over-quarter from $41.3 million in Q3 2025.
Moleculin Biotech (MBRX) Other Non-Current Liabilities (2016 - 2026) Analysis & Trends
Moleculin Biotech's Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $44000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $44000.0; the TTM figure through Dec 2025 stood at $44000.0 (changed N/A YoY), while the FY2025 annual figure was $44000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $44000.0, down from $41.3 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $41.3 million in Q3 2025, with the low at $1000.0 in Q3 2023.
- The 5-year median for Other Non-Current Liabilities is $1.6 million (2021), against an average of $5.4 million.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities plunged 99.69% in 2023, then soared 993100.0% in 2024.
- Moleculin Biotech's Other Non-Current Liabilities stood at $1.4 million in 2021, then sank by 94.55% to $77000.0 in 2022, then soared by 6205.19% to $4.9 million in 2023, then surged by 104.57% to $9.9 million in 2024, then slumped by 99.56% to $44000.0 in 2025.
- Business Quant data shows MBRX's Other Non-Current Liabilities at $44000.0 in Q4 2025, $41.3 million in Q3 2025, and $17.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Moleculin Biotech | 3.37 Mn | 3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Sep 30, 2025 | 41.33 Mn |
| Jun 30, 2025 | 16.97 Mn |
| Sep 30, 2024 | 9.93 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 3.40 Mn |
| Dec 31, 2023 | 4.86 Mn |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 38,000.00 |
| Dec 31, 2022 | 77,000.00 |
| Sep 30, 2022 | 228,000.00 |
| Jun 30, 2022 | 649,000.00 |
| Mar 31, 2022 | 1.25 Mn |
| Dec 31, 2021 | 1.41 Mn |
| Sep 30, 2021 | 3.71 Mn |
| Jun 30, 2021 | 5.39 Mn |
| Mar 31, 2021 | 6.56 Mn |
| Dec 31, 2020 | 8.19 Mn |